Kala-Azar and PKDL Treatment by Region (WHO 2026)
Gives the WHO 2026 kala-azar or PKDL regimen by region: paromomycin plus miltefosine in eastern Africa (or the alternatives), relapse combinations in South-East Asia, PKDL regimens, with doses by weight.
Open the tool → Runs in your browser. Data leaves only if you deliberately send a problem report from the interactive tool.
Example
- Region
- Eastern Africa
- Indication
- Primary VL
- Weight in kg
- 20
- Age in years
- 10
- Pregnant or breastfeeding
- No
- Other exclusion
- No
- HIV coinfection
- No
Result: Eastern Africa, primary VL: paromomycin sulfate 400 mg IM once a day (20 mg/kg = 15 mg/kg base) plus miltefosine 70 mg a day (35 mg twice a day) for 14 days, both for 14 days.
The tool opens with these values already filled in. Replace them with your own.
What you enter
- Region
- Indication
- Weight in kg
- Age in years
- Pregnant or breastfeeding
- Could become pregnant: reliable contraception assured
- Other exclusion (severe malnutrition, Hb under 5, severe VL, hearing loss, comorbidity, coinfection)
- Severely malnourished (PKDL)
- HIV coinfection
How this is calculated
Citation
WHO guidelines on leishmaniases: treatment of visceral leishmaniasis and post-kala-azar dermal leishmaniasis in eastern Africa and South-East Asia. Geneva: WHO; July 2026. Recommendations 1-4 and Annex 2. Read the source ↗
A reference and educational tool. Not medical, legal, or financial advice, and not a substitute for clinician judgment.